Richard Hubner

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +16

A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21

Ian Tomlinson, Emily L. Webb, Luis G. Carvajal‐Carmona et al. · Nature Genetics · 2007 · 809 citations

Life Sciences, Genetics, Molecular Genetics +14

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

Tim Meyer, Richard Fox, Yuk Ting et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 497 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

Zev A. Wainberg, Davide Melisi, Teresa Macarulla et al. · The Lancet · 2023 · 439 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12